Opexa, Merck KGaA deal
In March, the partners amended a February 2013 deal granting Merck’s Merck Serono division an exclusive option to license ex-Japan rights to develop and commercialize the biotech’s Tcelna imilecleucel-T to treat multiple sclerosis. Under the amendment, Opexa will provide Merck Serono with a detailed pre-Phase III plan by year end 2016. Merck’s option will expire 60 days after the joint steering committee approves the pre-Phase III plan. ...